MedElevator Войти в исследования
← Поиск публикаций

DOI 10.14309/ajg.0000000000003670

Медицинская библиотека · The American journal of gastroenterology · 2025

Patients Included in Clinical Trials of Biological Drugs for Inflammatory Bowel Disease Do Not Represent the Real-World Population.

Casas Deza Diego, Larrubia Domínguez Cristina, Pascual Oliver Andrea, Polo Cuadro Cristina, Yagüe Caballero Carmen, Almenara Michelena Laura, Royo Esteban Ana, Cotaina Gracia Andrea, Vicente Lidón Raquel, Corsino Roche Pilar, Cardona Usán Elena, Sirbu Sirbu Victor, Pardillos Ruiz Carlos, García López Santiago

СтатьяНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

INTRODUCTION

Clinical trials are the key to research in inflammatory bowel disease therapeutics. However, their external validity has been poorly evaluated, as have the outcomes in patients who do not meet the inclusion criteria.

METHODS

This retrospective observational study at Miguel Servet University Hospital, Zaragoza, Spain, included all consecutive patients diagnosed with Crohn's disease or ulcerative colitis who initiated biologic treatments between January 2017 and December 2022. Eligibility was assessed against the criteria of pivotal randomized clinical trials (RCTs) for adalimumab, infliximab, golimumab, ustekinumab, or vedolizumab. Clinical effectiveness and safety were evaluated at 14-16 weeks and 54 weeks, with treatment persistence assessed using survival analysis. Effectiveness and persistence were assessed to analyze whether patient selection has an impact on different clinical outcomes.

RESULTS

A total of 631 biologic treatments were initiated in 477 patients. Only 16.9% met the RCT criteria according to pivotal RCTs and 8% with newer RCTs. Disease-related criteria were the most frequently unmet (57.3%). Patients with ulcerative colitis were less likely to meet the criteria compared with patients with Crohn's disease (23% vs 4%, P < 0.001). No significant differences were observed in response rates, remission rates, adverse events, or drug discontinuation between eligible and noneligible patients. Survival analysis showed no differences in treatment persistence between both groups (hazard ratio 1.01, 95% confidence interval 0.73-1.38).

DISCUSSION: Only a minority of real-world patients with inflammatory bowel disease would qualify for corresponding RCTs, questioning the external validity of these trials. However, real-world use of biologics demonstrated similar effectiveness and safety in eligible and noneligible patients, underscoring the importance of practical clinical judgement in therapeutic decisions.

Для цитирования: Casas Deza Diego, Larrubia Domínguez Cristina, Pascual Oliver Andrea, Polo Cuadro Cristina, Yagüe Caballero Carmen, Almenara Michelena Laura, Royo Esteban Ana, Cotaina Gracia Andrea, Vicente Lidón Raquel, Corsino Roche Pilar, Cardona Usán Elena, Sirbu Sirbu Victor, Pardillos Ruiz Carlos, García López Santiago. Patients Included in Clinical Trials of Biological Drugs for Inflammatory Bowel Disease Do Not Represent the Real-World Population.. The American journal of gastroenterology. 2025. DOI: 10.14309/ajg.0000000000003670.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.